Chronotherapeutic Pulsatile Drug Delivery Systems in the Management of Type 2 Diabetes Mellitus: Advances and Future Perspectives

T2DM is among the widely prevalent metabolic disorders in existence and it is a massive health issue in the world. The material becomes poor as the body is not able to produce or utilize insulin properly which results in high blood sugar and the damage of the heart, kidneys and nerves in the long run. Essentially, the current lifestyle and dietary behaviours, as well as aging population, are all increasing the incidence of T2DM and hence an effective cure is a global agenda.¹ Majority of individuals either use oral hypoglycaemic drugs or insulin injections to maintain the blood sugar levels at a normal level but they are typically tailored to a constant dose and they do not consider the day-to-day variation in our bodies. That can become challenging to keep pace with the changes in glucose metabolism that occur during the day in reality.² Due to that, there has been growing interest among many regarding drug delivery systems able to be programmed to release drug based on biological processes of the body so that a person can achieve better results. The human body follows a 24-hour cycle which is to a great extent controlled by suprachiasmatic nucleus under the hypothalamus. The hormone release and the metabolism as well as sleep-wake is regulated by that inner clock. It goes even as far as to pull on glucose homeostasis, liver glucose production, and insulin sensitivity. A disturbance in those rhythms is associated with conditions such as obesity and type 2 diabetes, which are the disorders of the metabolism.^1,2 There are common circadian variations in glucose levels manifested by diabetics. The example of a classic one is the dawn phenomenon, during which the level of blood sugar increases at the beginning of the morning due to hormonal fluctuations and the insulin cycle in the body. This indicates the significance of timing of taking drugs and this is why we should have therapies that can administer drugs at the time when the body requires the drugs most.¹ This issue has provided chronotherapy with much hype in the research of pharma. Chronotherapy simply involves using drug on schedule relative to disease rhythms in order to achieve optimal effect and minimise side effects. It is already showing promise with the conditions with circadian patterns, such as asthma, high blood pressure, arthritis, and naturally diabetes.² Among all strategies, one of them is the pulsatile drug delivery systems (PDDS). They are intended to wait a predetermined lag time after which they discharge the full dose in succession with nature, and solve the disease at an opportune moment. PDDS is perfect when you do not want the drug to work all the time but at a certain point. Pharma tech has created a number of oral pulsatile delivery means in the last few years (capsules, press-coated tablets, osmotic systems, swelling-controlled systems and multiparticulate pellets).³ Pulsincap-like capsular systems have been intensively researched with regard to their programmable lag time and a high-rate release.⁴ Such systems are supposed to allow us to regulate the emergence of the drug depending on the circadian variations in the course of diseases. The aim is to increase the efficiency of therapy, enhance patient adherence, and decrease the frequency of the doses in chronotherapy.^3,5 This comprises the basics of the chronotherapeutic delivery, the various oral PDDS technologies, the mediums and procedures of testing them, and how all this can be applied to the treatment of type 2 diabetes. The latest findings, the present-day issues, and the perspectives in the area of chronotherapeutic pulsatile drug delivery are discussed as well.³

METHODOLOGY

The review article has been created on the basis of a systematic and thorough search of electronic databases such as PubMed, Scopus, ScienceDirect and Google Scholar containing publications published during the period 2000-2025, with particular attention paid to the latest developments (2020-2025). The inclusion criteria were limited to peer-reviewed research articles, review papers and clinical studies, all in English. Critical analysis was done on articles that dwelled on formulation strategies, pulsatile release mechanisms, chronopharmacology of antidiabetic medication, and clinical relevance. The extracted data were compared and synthesized to outline the existing trends, technology, constraints and future outlook in PDDS in diabetes management. To ensure that the quality and relevance of the review, irrelevant, duplicate and outdated studies were eliminated.

1. CIRCADIAN RHYTHM AND GLUCOSE HOMEOSTASIS
   1. Circadian Regulation Molecular Mechanism

Circadian rhythms are just natural cycles of 24 hours that regulate half the planet of physiological and metabolic activities. The central pacemaker in the hypothalamus suprachiasmatic nucleus (SCN) plays the principal role in the maintenance of the breast of the clock in mammals. The peripheral clocks are everywhere within the body and they are important in glucose homeostasis because they control the time of metabolic gene expression as well as the secretion of hormones.⁶ These rhythms are molecular-based and facilitated by transcription-translation feedback loop which works with core clock genes. CLOCK and BMAL1 initiate PER and CRY genes; the proteins accumulated by the genes feedback, and inhibit CLOCK-BMAL1 activity. There is also the hormonal homeostasis which is closely circadian regulated and this is glucocorticoids, insulin, among other metabolic hormones which maintain the balance.⁷ Research indicates that the clock is capable of controlling such processes as glucose uptake, gluconeogenesis and glucagon metabolism. Chemical activities are synchronized with our every-day eating and starvation rhythms by these oscillations. When you manipulate these clock genes, metabolic dysfunction that predisposes people to obesity, or type 2 diabetes can be observed.^8,9

Figure.1: Cycle of Circadian Rhythm

1. 2. Circadian Variation in Insulin Secretion

Insulin secretion and glucose metabolism have an apparent circadian oscillation throughout the day. The secretion of insulin is adjusted to our fasting-feeding orations in order to maintain the blood sugar concentration constant. Pancreatic beta cells possess their small clocks that synchronize the oscillatory expression of the insulin-production, insulin- secretion, glucose-sensing genes.¹⁰ They have discovered that the insulin sensitivity and glucose tolerance vary with the time of the day- usually it is quite high during the morning compared to at night. The reason is that the release of insulin and the peripheral sensitization is controlled by the circadian rhythms. Sleep and circadian rhythms have an enormous role in the glucose regulation as well; insulin sensitivity and glucose tolerance may be reduced by the lack of sleep or circadian disruption.¹¹

In a recent randomized controlled clinical study (2024) in night-shift workers, the effects of circadian disruption on the insulin sensitivity and glucose metabolism were revealed. Those who were exposed to circadian misalignment in this study had a considerably lower insulin sensitivity and glucose regulation than when it was aligned. Also, melatonin administration enhanced insulin sensitivity and circadian rhythmicity, which is a direct indication of the biological clock control of glucose homeostasis and insulin secretion. These results are excellent clinical arguments that disruption to circadian rhythms has a detrimental impact on insulin dynamics and glucose tolerance, and that chronobiological regulation is crucial in the control of metabolism.¹²

1. 3. Dawn Phenomenon in Type 2 Diabetes

In human beings with diabetes, the morning glucose peak is known as the dawn phenomenon and typically occurs between 4:00am and 8:00am. This increase does not stem from low night time blood sugar levels but is associated with hormonal fluctuation during the early morning. Liver glucose production is increased by the nighttime surge of growth hormone; an anti-insulin hormone. Large quantities of growth hormone generated within a sleep may aggravate insulin-resistance and initiate morning hyperglycaemia. Glucose metabolism is also a tweaker of other circadian rhythm hormone such as cortisol and catecholamines. Various causes of increased severity of the dawn phenomenon among type-2 diabetics comprise defective secretion of insulin and amplified insulin resistance that result in the continued morning hyperglycaemia and a lack of capability to maintain the level of blood glucose.¹³

In a post-hoc analysis of a randomized controlled trial, Wang et al. (2021) observed that the rise in the dawn phenomenon was 35.9+-17.9 mg/dL of nocturnal glucose nadirs of 123.9+-40.7 mg/dL in 50 adults with type 2 diabetes (aged 53.5+-8.2 years, HbA1c 8.4+-1.2) who had previously taken metformin. Glibenclamide (n=23) had no effect, but administering acarbose (n=27) substantially reduced this to 28.3+-16.5 mg/dL (p=0.037) and decreased the mean amplitude of glycaemic level fluctuations to 71.4 mg/dL. These results highlight the benefits of alpha-glucosidase inhibitors in addressing circadian irregularities and the association connecting the dawn phenomenon and daily glucose changes.¹⁴

2. CHRONOTHERAPY PRINCIPLE OF DIABETES MANAGEMENT
   1. Chronotherapy and Chrono Pharmacology of Antidiabetic Agents

Chronotherapy in diabetes aims at matching drug use with the circadian rhythms with the goal of maximizing therapeutic effect and reducing adverse effects. The temporal changes in physiological activities, including the secretion of insulin, the tolerance to glucose, the production of hepatic glucose, and hormone control play a significant role in the pharmacodynamics and pharmacokinetics of antidiabetic agents. Chronopharmacology specifically studies the effects of these biological rhythms on drug absorption, distribution, metabolism and excretion, which results in time-dependent changes in drug response. In type 2 diabetes, the decreased insulin sensitivity at night time and the elevated hepatic glucose synthesis in early mornings indicate the role of timed drug administration. Properly timed intake of antidiabetic medications can aid in the enhancement of glycemic control, elevate drug response, and decrease chance of hypoglycemia. Therefore, by incorporating the concept of chronopharmacology into the therapeutic approaches, it will be possible to manage diabetes in a more specific and more physiologically aligned way.¹⁵

1. 2. Time Specificity of Drug Administration:

The time-release delivery technologies have become a defining modality in the improvement of the diabetes therapy. These systems are designed to convey pharmacological agents where intervals are preset to coincide with circadian intervals in glucose metabolism perturbation. These strategies come in especially handy in the reduction of such phenomena as early-morning hyperglycaemia also known as the dawn phenomenon.¹⁶ Pulsatile drug delivery systems and chronotherapeutic formulations have a predetermined lag time in order to generate desired drug release so that optimum therapeutic concentrations occur during periods of physiological need. This model increases patient compliance, increases glycemic attitudes, and reduces negative incidents related to standard dosing schedules.¹⁵ Overall, the concept of chronotherapy has a great potential in the management of diabetes through the coordination of the pharmacotherapy with the natural biological rhythms of the body which enhances treatment efficacy and physiological homeostasis.

3. OVERVIEW OF PULSATILE DRUG DELIVERY SYSTEMS (PDDS)
   1. Concept and Major Characteristics

Pulsatile drug delivery systems (PDDS) are novel drug delivery systems that release the active pharmaceutical ingredient rapidly in a pulse format upon a set lag time, as opposed to a continuous release. They are especially useful in the treatment of diseases with circadian regulation, the symptoms of which vary over time, e.g. diabetes, asthma, and hypertension. PDDS are able to synchronize drug delivery to biological rhythms, so that therapeutic levels can be attained when the body is at peak demand.¹⁷ The given approach helps improve the therapeutic efficacy, decrease the exposure to unnecessary drugs, and decrease adverse effects. Its defining feature is that it is characterized by a defined lag period during which there is little or no release of drugs, followed by one sharp and complete release pulse, and this is done by capsular system, osmotic devices, rupturable coatings, and plug-based systems that can be used to accurately control when the drug is released.^18,19

Figure.2: Drug release profile from PDDS vs. conventional vs. delayed release

Where, A: Conventional release profile, B: Burst release of drug after a lag time, C: Delayed release profile after a lag time, D: Constant release profile in prolonged period after a lag time, E: Extended-release profile without lag time.

• 2. Pulsatile over sustained release systems
• Offers drug release on a time control that is in line with the circadian rhythm of illnesses.
• Increases the treatment efficacy by releasing the drug at the peak of symptoms.
• Cuts down the tolerance of drugs and tachyphylaxis due to prolonged drug exposure.
• Increases patient compliance as a result of lower dosing schedule.
• Applicable to drugs with short half-life which need frequent ingestion.
• Applicable in treatment of diseases that are chronotherapeutic like asthma, hypertension, arthritis and diabetes.

4. ORAL PULSATILE DRUG DELIVERY TECHNOLOGIES

The purpose of oral pulsatile delivery systems is to administer drugs in a time regulated form after a preset delay then adopt a rapid release of the drug.²⁰ Such systems have been applied specifically in the treatment of the ailments that display circadian rhythms whereby the symptoms become evident at a given time of the day.²¹

Table 1: Pulsatile drug delivery technologies and its mechamism²¹

SYSTEM	MECHANISM	KEY FEATURES
Capsular-Based Systems	Drug is contained in a closed capsule body with a hydrogel/polymeric plug which swells or erodes on contact with GI fluids resulting in plug expulsion and release of drug fast after a lag time	Minimal design, manufacturing, fine control of lag time, chronotherapy.22
Rupturable Coating Systems	Drug core is covered with a polymer layer which breaks on the internal pressure caused by swelling or osmotic agents after penetration by fluids.	Sharp burst release, adjustable lag time through coating thickness and composition.23
Soluble/ Erodible Membrane Systems	The Outer polymeric coating (e.g., HPMC or lipid layer) dissolves or erodes with time, regulating lag phase prior to drug release.	Lag time is dependent on coating thickness and viscosity; easy and predictable release mechanism.24
Osmosis-Based Systems	Drug release due to osmotic pressure created by the inflow of water through a semipermeable membrane after a threshold is met or through an orifice.	Controlled and reproducible discharge, to some extent regardless of GI conditions.25,26
Multi-Unit Pellet Systems	Multiple drug-loaded pellets whose polymer coatings have varying lag times give staggered lag times, which leads to sequential or multiple pulse releases.	Dumping of reduced dose, even distribution of GI, flexible release profiles, better safety.22

Figure.3: Capsular-Based Systems²²

Figure.4: Rupturable Coating Systems²³

Figure.5: Delivery system with soluble or erodible membranes²⁴

8. RESEARCH GAP AND FUTURE SCOPE

Regardless of the significant progress, there are still a number of important gaps in the clinical translation of the chronotherapeutic pulsatile drug delivery systems (PDDS) to treat type 2 diabetes. The majority of systems remain in preclinical studies, with little large-scale clinical data on their long-term safety and effectiveness.³⁹ Moreover, it is still hard to realize the same and reproducible lag time in vivo because of the variability of gastrointestinal physiology and circadian rhythms across individuals.⁴⁰ Legal obstacles, such as absence of standardized guidelines and poor in vitro-in vivo overlap (IVIVC) also hinder the development and commercialization of such systems.⁴¹ Furthermore, existing formulations are not personal enough to deal with individual patient metabolic and circadian differences. Subsequent studies ought to then involve the creation of intelligent, glucose reactive delivery mechanisms blended with digital health technologies including continuous glucose sensors and wearable gadgets. The integration of artificial intelligence and machine learning of real-time data analysis and adaptive dosing also promise great potential in the development of individualized chronotherapy and a better glycemic outcome.⁴²

9. CONCLUSION

The introduction of chronotherapeutic pulsatile drug delivery systems is an innovative and promising way of managing type 2 diabetes mellitus, whereby the release of drugs is synchronized with circadian changes in glucose metabolism and insulin release. The systems have considerable benefits compared to traditional dosage forms, such as enhanced therapeutic effect, minimized side effects, and increased patient compliance. Pulsatile systems of capsular, osmotic pumps, multiparticulate formulations, and stimuli-responsive platforms have also enhanced the potential of PDDS to provide time-controlled drug delivery. Nevertheless, issues like variability in lag time, lack of clinical validation, and manufacturing complications have been some of the obstacles to extensive clinical use. The accuracy and efficiency of chronotherapy is likely to become more precise and effective with the integration of smart drug delivery systems with digital health technologies and the personalization of medicine methods in the future. In general, PDDS has great potential to revolutionize diabetes management by offering more physiological and patient-centric approaches to treatment.

REFERENCES

1. Jough SS, Singh SP, Singh Y, Gupta D, Saxena P, Gupta S, Singh A, Srivastva A. Chronopharmacology: Recent advancements in the treatment of diabetes mellitus through chronotherapy. Int J Pharm Pharm Sci. 2017;9(2):87-99.
2. Zeeshan M, Hu J, Mao CX, Danish A, Xiong Y, Irshad MS, Dao VD, Liu Z. Nanomaterial-enabled drug delivery systems for circadian medicine: bridging direct rhythm modulation and chronotherapy. RSC advances. 2025;15(38):31981-2008.
3. Anusha V, Umashankar MS, Kumar YG. Pulsatile drug delivery system—an innovative method to treat chronotherapeutic diseases by synchronizing drug delivery with circadian rhythm. Journal of Applied Pharmaceutical Science. 2023 5;13(12):066-78.  
4. Butler CT, Rodgers AM, Curtis AM, Donnelly RF. Chrono-tailored drug delivery systems: recent advances and future directions. Drug Delivery and Translational Research. 2024 Jul;14(7):1756-75.
5. Ali J, Baboota S, Ahuja A, Saigal N. Distinctive features of chronotherapeutic and pulsatile drug delivery systems. J Drug Target. 2010;18(6):413-419.
6. Gachon F, Loizides-Mangold U, Petrenko V, Dibner C. Glucose homeostasis: regulation by peripheral circadian clocks in rodents and humans. Endocrinology. 2017 1;158(5):1074-84.
7. Gnocchi D, Bruscalupi G. Circadian rhythms and hormonal homeostasis: pathophysiological implications. Biology. 2017 4;6(1):10.  
8. McGinnis GR, Young ME. Circadian regulation of metabolic homeostasis: causes and consequences. Nature and science of sleep. 2016 27:163-80.
9. Serin Y, Acar Tek N. Effect of circadian rhythm on metabolic processes and the regulation of energy balance. Annals of Nutrition and Metabolism. 2019 28;74(4):322-30.
10. Kalsbeek A, la Fleur S, Fliers E. Circadian control of glucose metabolism. Molecular metabolism. 2014 1;3(4):372-83.
11. Tran HT, Kondo T, Ashry A, Fu Y, Okawa H, Sawangmake C, Egusa H. Effect of circadian clock disruption on type 2 diabetes. Frontiers in Physiology. 2024 Aug 6; 15:1435848.
12. Hannemann J, Laing A, Middleton B, Schwedhelm E, Marx N, Federici M, Kastner M, Skene DJ, Böger R. Effect of oral melatonin treatment on insulin resistance and diurnal blood pressure variability in night shift workers. A double-blind, randomized, placebo-controlled study. Pharmacological Research. 2024; 199:107011.
13. Peng F, Li X, Xiao F, Zhao R, Sun Z. Circadian clock, diurnal glucose metabolic rhythm, and dawn phenomenon. Trends in neurosciences. 2022 1;45(6):471-82.
14. Wang JS, Lee IT, Lee WJ, Lin SD, Su SL, Tu ST, Lin SY, Sheu WH. The dawn phenomenon in type 2 diabetes: its association with glucose excursions and changes after oral glucose-lowering drugs. Therapeutic Advances in Chronic Disease. 2021 12:20406223211033674.
15. Sagar A, Jough S. Chronopharmacology: Recent advancements in the treatment of diabetes mellitus through chronotherapy. Int J Pharm Pharm Res (IJPPR Human). 2017;9(2):87–99.
16. Kashyap S, Bala R, Behl T. Understanding the concept of chronotherapeutics in the management of diabetes mellitus. Current Diabetes Reviews. 2021 1;17(5):19-25.
17. Reddy GG, Jat RK, Manjanna KM. Design, evaluation and optimization of albuterol sulphate and theophylline pulsincap drug delivery system for chronotherapy of asthma. J Drug Deliv Ther. 2024;14(2):134–41.
18. Beg S, Swain S, Gahoi S, Kohli K. Design, development and evaluation of chronomodulated drug delivery systems of amoxicillin trihydrate with enhanced antimicrobial activity. Curr Drug Deliv. 2013;10(2):174–87.
19. Anusha V, Umashankar MS, Kumar YG. Pulsatile drug delivery system—an innovative method to treat chronotherapeutic diseases by synchronizing drug delivery with circadian rhythm. J Appl Pharm Sci. 2023;13(12):66–78.
20. Singh B, Trivedi M, Jain R. A research project on design and evaluation of colon targeted modified Pulsincap delivery. Journal of Pharmaceutical Research. 2014;14(23):1593-607.
21. Rewar S, Bansal BK, Singh CJ, Sharma AK, Pareek R. Pulsatile drug delivery system: an overview. Journal of Global Trends in Pharmaceutical Sciences. 2014;5(3):1943-55.
22.  Bodke VI, Tekade BW, Badekar RU, Phalak SD, Kale MO. Pulsatile drug delivery systems: the novel approach. International Journal of Pharmacy and Pharmaceutical Sciences. 2024;16(2):1-11.
23.  Sridevi S. Formulation and in vitro evaluation of apremilast pulsincap drug delivery. World Journal of Pharmaceutical Sciences. 2025 4.
24. Waqar MA, Mubarak N, Khan AM, Khan R, Shaheen F, Shabbir A. Advanced polymers and recent advancements on gastroretentive drug delivery system; a comprehensive review. Journal of drug targeting. 2024 2;32(6):655-71.
25. Almoshari Y. Osmotic pump drug delivery systems—a comprehensive review. Pharmaceuticals. 2022 18;15(11):1430.
26. Navarro-Tumar D, García-Merino B, González-Fernández C, Ortiz I, San-Román MF, Bringas E. Novel applications in controlled drug delivery systems by integrating osmotic pumps and magnetic nanoparticles. Sensors. 2024 31;24(21):7042.
27. Amiama-Roig A, Verdugo-Sivianes EM, Carnero A, Blanco JR. Chronotherapy: circadian rhythms and their influence in cancer therapy. Cancers. 2022 17;14(20):5071.
28. Chong MY, Henson J, Bours MJ, Bosma H, de Galan BE, van der Kallen CJ, Meertens RM, Savelberg HH, Schram MT, Weijenberg MP, Yates T. Physical activity and meal timing alignment with chronotype and their associations with glucose metabolism: The Maastricht Study. Diabetes, Obesity and Metabolism. 2026;28(4):3295-304.
29. Lee SH, Hofstede RP, de la Colina AN, Gunton JH, Bernstock JD, Traverso G. Implantable systems for neurological chronotherapy. Advanced Drug Delivery Reviews. 2025 1; 221:115574.
30. Rajput M, Sharma R, Kumar S, Jamil F, Sissodia N, Sharma S. Pulsatile drug delivery system: a review. International journal of research in pharmaceutical and biomedical sciences. 2012;3(1):118-24.
31. Anusha V, Umashankar MS, Kumar YG. Pulsatile drug delivery system—an innovative method to treat chronotherapeutic diseases by synchronizing drug delivery with circadian rhythm. Journal of Applied Pharmaceutical Science. 2023 5;13(12):066-78.
32. Forrestel AC, Miedlich SU, Yurcheshen M, Wittlin SD, Sellix MT. Chronomedicine and type 2 diabetes: shining some light on melatonin. Diabetologia. 2017;60(5):808-22.
33. Bodke VI, Tekade BW, Badekar RU, Phalak SD, Kale MO. Pulsatile drug delivery systems the novel approach. Int J Pharm Pharm Sci. 2024;16(2):1-1.
34. Narendra Sharma, Pushpendra Kumar Saini, CP Mishra and Chanchal Sharma. Pulsatile drug delivery: Advances, mechanisms and future perspectives. International Journal of Pharmacy and Pharmaceutical Science 2025; 7(2): 229-232
35. Dey NS, Majumdar S, Rao M. Multiparticulate drug delivery systems for controlled release. Trop J Pharm Res. 2018;17: 1067-1075
36. Ravula AN, Goud BA, “Recent Advances in Oral Pulsatile Drug Delivery” Journal of Advanced Pharmaceutical Sciences 2011; 1:57-62.
37. Sahu RK, Yadav R, Prasad P. Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. SpringerPlus. 2014; 3:695-705.
38. http://www.aptalispharmaceuticaltechnolo gies.com/tech_orbexa.html (Date of access06/07/2014).
39. Renzu M, Hubers C, Conway K, Gibatova V, Mehta V, Taha W, Hubers CM. Emerging technologies in endocrine drug delivery: innovations for improved patient care. Cureus. 2024 Jun 13;16(6). PMID: 39006724
40. Liu J, Yi X, Zhang J, Yao Y, Panichayupakaranant P, Chen H. Recent Advances in the Drugs and Glucose-Responsive Drug Delivery Systems for the Treatment of Diabetes: A Systematic Review. 
41. Kwon SY, Moon JS. Advances in continuous glucose monitoring: clinical applications. Endocrinology and Metabolism. 2025 Apr 8;40(2):161-73.
42. Wang G, Liu X, Ying Z, Yang G, Chen Z, Liu Z, Zhang M, Yan H, Lu Y, Gao Y, Xue K. Optimized glycemic control of type 2 diabetes with reinforcement learning: a proof-of-concept trial. Nature Medicine. 2023 Oct;29(10):2633-42.